{"id":"https://openalex.org/W7204732269","doi":"https://doi.org/10.1016/s2152-2650(26)00975-4","title":"POSTER: MPN-1076: Hematologic and Safety Profile of Epetraborole in a Non-Polycythemia Vera Patient Population","display_name":"POSTER: MPN-1076: Hematologic and Safety Profile of Epetraborole in a Non-Polycythemia Vera Patient Population","publication_year":2026,"publication_date":"2026-08-01","ids":{"openalex":"https://openalex.org/W7204732269","doi":"https://doi.org/10.1016/s2152-2650(26)00975-4"},"language":"en","primary_location":{"id":"doi:10.1016/s2152-2650(26)00975-4","doi":"https://doi.org/10.1016/s2152-2650(26)00975-4","is_oa":false,"landing_page_url":"https://doi.org/10.1016/s2152-2650(26)00975-4","pdf_url":null,"source":{"id":"https://openalex.org/S186546955","display_name":"Clinical Lymphoma Myeloma & Leukemia","issn_l":"2152-2669","issn":["2152-2669","2152-2650"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-d","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-70","russia-white-list-3","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Clinical Lymphoma Myeloma and Leukemia","raw_type":"journal-article"},"volume":null,"type":"article","is_traditional":true,"indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5080609948","display_name":"George H. Talbot","orcid":"https://orcid.org/0000-0002-2868-2707","observed_orcids":["https://orcid.org/0000-0002-2868-2707"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"George H Talbot","raw_affiliation_strings":["Talbot Advisors, Bradenton, FL, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Talbot Advisors, Bradenton, FL, USA","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5019470085","display_name":"Stanton L. Gerson","orcid":"https://orcid.org/0000-0003-3106-2549","observed_orcids":["https://orcid.org/0000-0003-3106-2549"]},"institutions":[{"id":"https://openalex.org/I58956616","display_name":"Case Western Reserve University","ror":"https://ror.org/051fd9666","country_code":"US","type":"education","lineage":["https://openalex.org/I58956616"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Stanton Gerson","raw_affiliation_strings":["CaseWestern Reserve University School of Medicine, Cleveland, OH, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"CaseWestern Reserve University School of Medicine, Cleveland, OH, USA","institution_ids":["https://openalex.org/I58956616"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5025173642","display_name":"Bibiana Casta\u00f1eda-Ruiz","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Bibiana Casta\u00f1eda-Ruiz","raw_affiliation_strings":["AN2 Therapeutics, Inc, San Jose, CA, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"AN2 Therapeutics, Inc, San Jose, CA, USA","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5110084290","display_name":"Alex Smith","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Alex Smith","raw_affiliation_strings":["AN2 Therapeutics, Inc, San Francisco, CA, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"AN2 Therapeutics, Inc, San Francisco, CA, USA","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5148667801","display_name":"Stephanie Moore","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Stephanie Moore","raw_affiliation_strings":["AN2 Therapeutics, Inc, Menlo Park, CA, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"AN2 Therapeutics, Inc, Menlo Park, CA, USA","institution_ids":[]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5148734166","display_name":"Sanjay Chanda","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Sanjay Chanda","raw_affiliation_strings":["AN2 Therapeutics, Inc, Menlo Park, CA, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"AN2 Therapeutics, Inc, Menlo Park, CA, USA","institution_ids":[]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":1,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":{"value":3890,"currency":"USD","value_usd":3890},"apc_paid":null,"fwci":0.0,"has_fulltext":false,"cited_by_count":0,"citation_normalized_percentile":{"value":0.0,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":null,"biblio":{"volume":"26","issue":null,"first_page":"S287","last_page":"S287"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T11628","display_name":"Myeloproliferative Neoplasms: Diagnosis and Treatment","score":0.8398000001907349,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T11628","display_name":"Myeloproliferative Neoplasms: Diagnosis and Treatment","score":0.8398000001907349,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10309","display_name":"Acute Myeloid Leukemia Research","score":0.07180000096559525,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11157","display_name":"Chronic Lymphocytic Leukemia Research","score":0.019300000742077827,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/myeloproliferative-neoplasms","display_name":"myeloproliferative neoplasms","score":0.9449999928474426},{"id":"https://openalex.org/keywords/drug-safety","display_name":"drug safety","score":0.49799999594688416},{"id":"https://openalex.org/keywords/jak-inhibitors","display_name":"JAK inhibitors","score":0.3529999852180481}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.9725000262260437},{"id":"https://openalex.org/C3018359032","wikidata":"https://www.wikidata.org/wiki/Q1550789","display_name":"Safety profile","level":3,"score":0.7031999826431274},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.4551999866962433},{"id":"https://openalex.org/C2908647359","wikidata":"https://www.wikidata.org/wiki/Q2625603","display_name":"Population","level":2,"score":0.4375999867916107},{"id":"https://openalex.org/C2779328685","wikidata":"https://www.wikidata.org/wiki/Q1475557","display_name":"Patient safety","level":3,"score":0.3230000138282776},{"id":"https://openalex.org/C187212893","wikidata":"https://www.wikidata.org/wiki/Q123028","display_name":"Pediatrics","level":1,"score":0.3082999885082245},{"id":"https://openalex.org/C61511704","wikidata":"https://www.wikidata.org/wiki/Q1671857","display_name":"Incidence (geometry)","level":2,"score":0.30640000104904175},{"id":"https://openalex.org/C194828623","wikidata":"https://www.wikidata.org/wiki/Q2861470","display_name":"Emergency medicine","level":1,"score":0.29589998722076416},{"id":"https://openalex.org/C177713679","wikidata":"https://www.wikidata.org/wiki/Q679690","display_name":"Intensive care medicine","level":1,"score":0.2847000062465668},{"id":"https://openalex.org/C2779473830","wikidata":"https://www.wikidata.org/wiki/Q1540899","display_name":"MEDLINE","level":2,"score":0.2842000126838684},{"id":"https://openalex.org/C2908731994","wikidata":"https://www.wikidata.org/wiki/Q2509220","display_name":"Hematologic Neoplasms","level":3,"score":0.27390000224113464},{"id":"https://openalex.org/C535046627","wikidata":"https://www.wikidata.org/wiki/Q30612","display_name":"Clinical trial","level":2,"score":0.26739999651908875},{"id":"https://openalex.org/C2778837598","wikidata":"https://www.wikidata.org/wiki/Q948318","display_name":"Polycythemia vera","level":2,"score":0.25859999656677246},{"id":"https://openalex.org/C2776112149","wikidata":"https://www.wikidata.org/wiki/Q7383611","display_name":"Ruxolitinib","level":4,"score":0.2583000063896179}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1016/s2152-2650(26)00975-4","doi":"https://doi.org/10.1016/s2152-2650(26)00975-4","is_oa":false,"landing_page_url":"https://doi.org/10.1016/s2152-2650(26)00975-4","pdf_url":null,"source":{"id":"https://openalex.org/S186546955","display_name":"Clinical Lymphoma Myeloma & Leukemia","issn_l":"2152-2669","issn":["2152-2669","2152-2650"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-d","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-70","russia-white-list-3","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Clinical Lymphoma Myeloma and Leukemia","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[{"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3","score":0.9763000011444092}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W7204722226","https://openalex.org/W7204718928","https://openalex.org/W7204720033","https://openalex.org/W4386270935","https://openalex.org/W7204718042","https://openalex.org/W7204713382","https://openalex.org/W4413810145","https://openalex.org/W4386282062","https://openalex.org/W7204689236","https://openalex.org/W4413809692"],"abstract_inverted_index":null,"counts_by_year":[],"updated_date":"2026-11-12T12:28:57.059296","created_date":"2026-08-31T00:00:00"}